Literature DB >> 2170472

Itraconazole in tinea versicolor: a review.

J Delescluse1.   

Abstract

Itraconazole, a new orally active triazole antifungal, has been tested in patients with pityriasis versicolor. A number of studies have shown that itraconazole is effective for this mild fungal skin disease. The total dose required for effective treatment is 1000 mg, and it has been given as 200 mg for 5 days or 7 days. The organisms disappear slowly from the skin, even when dead, and the results should be assessed clinically and mycologically at around 3 to 4 weeks after treatment. Numerous studies have shown that itraconazole is superior to placebo and as effective as selenium sulfide, clotrimazole, and ciclopirox olamine. It is also better tolerated by patients than selenium sulfide.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2170472     DOI: 10.1016/0190-9622(90)70252-d

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  4 in total

1.  A modified Christensen's urea and CLSI broth microdilution method for testing susceptibilities of six Malassezia species to voriconazole, itraconazole, and ketoconazole.

Authors:  S Rincón; M C Cepero de García; A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

Review 2.  Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections.

Authors:  M Haria; H M Bryson; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

3.  Randomized comparative clinical trial of Artemisia sieberi 5% lotion and clotrimazole 1% lotion for the treatment of pityriasis versicolor.

Authors:  Farrokh Rad; Farzad Aala; Naser Reshadmanesh; Rokshana Yaghmaie
Journal:  Indian J Dermatol       Date:  2008       Impact factor: 1.494

Review 4.  Malassezia-Associated Skin Diseases, the Use of Diagnostics and Treatment.

Authors:  Ditte M L Saunte; George Gaitanis; Roderick James Hay
Journal:  Front Cell Infect Microbiol       Date:  2020-03-20       Impact factor: 5.293

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.